Trius, Bayer deal

Trius granted Bayer exclusive rights to antibiotic candidate torezolid in China, Japan, Africa, Latin America, the Middle East, and all other countries in Asia, excluding North and South Korea. Trius will receive $25 million up front and is eligible for up to $69 million in milestones, plus double-digit royalties. Additionally, Bayer will cover all development costs in China and Japan, where territory specific trials are required. The pharma will also be responsible for about 25% of the global development costs of torezolid in acute bacterial skin and skin structure infections (ABSSSIs) and pneumonia. ...